Audrey Grain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Audrey Grain has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
- Marion Eveillard
Hematology Biology Nantes University Hospital Nantes France
5 shared publications - Baptiste Le Calvez
Pediatric Oncology Nantes University Hospital Nantes France
4 shared publications Caroline Thomas
Nantes Université, CHU Nantes, INSERM, pediatric hematology et oncology department, CIC 1413, F-44000 Nantes, France, University Hospital Centre Nantes, Nantes, France
4 shared publications- Jocelyn Ollier
CRCI2NA, Nantes Université, Université d’Angers, Inserm UMR 1307, CNRS UMR 6075, F-44000 Nantes, 49000 Angers, France
4 shared publications Virginie Gandemer
Oncologie et hématologie pédiatrique, CHU de Rennes, Rennes, France
4 shared publications- Béatrice Clémenceau
Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, F-44007 Nantes, France
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in Bulletin du Cancer
Usage des antibiotiques en post-allogreffe de CSH pédiatrique (SFGM-TC)
- 30 September 2026
- Published by Elsevier in Bulletin du Cancer
Open AccessUsage des antibiotiques en post-allogreffe de CSH pédiatrique (SFGM-TC)
- 16 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70705
Daratumumab in Combination With High‐Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T‐Cell Acute Lymphoblastic Leukemia: A Case Report
Patients with refractory or relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) have dismal outcomes. While immunotherapies are growing opportunities for B‐cell ALL, targeted therapies for T‐ALL remain limited. The CD38 antigen, steadily expressed on T‐ALL blasts, represents a relevant therapeutic target. Daratumumab, an anti‐CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T‐ALL. We report here the achievement of a third complete response with the combination of daratumumab, high‐dose cytarabine (18 g/m 2 ), and amsacrine in an 11‐year‐old patient with highly aggressive relapsed T‐ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.
- 16 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70705
Daratumumab in Combination With High‐Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T‐Cell Acute Lymphoblastic Leukemia: A Case Report
Patients with refractory or relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) have dismal outcomes. While immunotherapies are growing opportunities for B‐cell ALL, targeted therapies for T‐ALL remain limited. The CD38 antigen, steadily expressed on T‐ALL blasts, represents a relevant therapeutic target. Daratumumab, an anti‐CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T‐ALL. We report here the achievement of a third complete response with the combination of daratumumab, high‐dose cytarabine (18 g/m 2 ), and amsacrine in an 11‐year‐old patient with highly aggressive relapsed T‐ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.
- 22 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (4) , 390-401
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort
Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric myeloproliferative neoplasm for which hematopoietic stem cell transplantation (HSCT) is currently the only established curative therapy. However, a watch-and-wait (W&W) approach has shown promise for long-term survival in selected cases. In this real-world study, we analyzed outcomes of patients with JMML initially managed with a W&W strategy within a nationwide cohort of 161 genetically characterized cases. W&W was chosen for 35 patients, with increasing adoption over time, reaching 39% in the 2016-to-2021 period. Most patients carried mutations in CBL (43%), NRAS (34%), or homozygous germ line SH2B3 (14%). Over a median follow-up of 6.5 years, 30 of 35 (86%) achieved long-term survival with partial or complete resolution of myeloproliferative symptoms, although clonal hematopoiesis persisted in nearly all survivors (18/20). Disease progression occurred in 5 patients (CBL, n = 3; NRAS, n = 1; PTPN11, n = 1), mostly within 2 years after diagnosis. Overall, in the W&W cohort, the 5-year overall and event-free survivals were 93.1% and 84.5%, respectively. In NRAS-mutated cases, age of 45 × 109/L, the absence of additional somatic mutations, and low DNA methylation profile were associated with favorable outcomes. In CBL-driven JMML, no predictive factor of adverse evolution was identified. Notably, W&W was effective in all patients with homozygous germ line SH2B3. These findings support W&W as a viable alternative in up to 30% of patients with JMML, potentially sparing them from HSCT-associated risks. Given the persistence of clonal hematopoiesis and the risk of extrahematological complications, long-term monitoring remains essential.
- 22 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (4) , 390-401
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort
Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive pediatric myeloproliferative neoplasm for which hematopoietic stem cell transplantation (HSCT) is currently the only established curative therapy. However, a watch-and-wait (W&W) approach has shown promise for long-term survival in selected cases. In this real-world study, we analyzed outcomes of patients with JMML initially managed with a W&W strategy within a nationwide cohort of 161 genetically characterized cases. W&W was chosen for 35 patients, with increasing adoption over time, reaching 39% in the 2016-to-2021 period. Most patients carried mutations in CBL (43%), NRAS (34%), or homozygous germ line SH2B3 (14%). Over a median follow-up of 6.5 years, 30 of 35 (86%) achieved long-term survival with partial or complete resolution of myeloproliferative symptoms, although clonal hematopoiesis persisted in nearly all survivors (18/20). Disease progression occurred in 5 patients (CBL, n = 3; NRAS, n = 1; PTPN11, n = 1), mostly within 2 years after diagnosis. Overall, in the W&W cohort, the 5-year overall and event-free survivals were 93.1% and 84.5%, respectively. In NRAS-mutated cases, age of 45 × 109/L, the absence of additional somatic mutations, and low DNA methylation profile were associated with favorable outcomes. In CBL-driven JMML, no predictive factor of adverse evolution was identified. Notably, W&W was effective in all patients with homozygous germ line SH2B3. These findings support W&W as a viable alternative in up to 30% of patients with JMML, potentially sparing them from HSCT-associated risks. Given the persistence of clonal hematopoiesis and the risk of extrahematological complications, long-term monitoring remains essential.
- Open Access
- 3 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012552
Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALL
Background: Blinatumomab, inotuzumab or autologous anti-CD19 chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, tumor escape through antigenic modulation accounts for almost 40% of subsequent relapses. Multi-antigen targeting strategies should be developed, and it is urgent to identify new targets. Methods: We investigated the extensive immunophenotyping of 13 BCP-ALL from pediatric patients by using the BioLegend Human Cell Surface Marker Screening Kit. Then, to assess whether targeting each antigen with monoclonal antibodies could lead to leukemic cell lysis, long-term antibody-dependent cellular cytotoxicity (ADCC) assays were performed using murine monoclonal antibodies and human T cells armed with murine CD16. Results: 13 highly expressed antigens were selected. With the antibodies tested here, the most significant lysis was observed by targeting CD24 and CD156c. The double targeting of CD24-CD123 appeared to be even more effective. Triple targeting was associated with a reduction in ADCC activity. Conclusion: CD24 therefore emerged as an effective target in BCP-ALL, and the combination of CD24 and CD123 as a potential effective double-targeting strategy. The combination of different recognition modalities (eg, a CAR and CD16) should be tested to determine whether it provides synergistic cytotoxic activity in triple targeting.
- 3 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012552
Open AccessEvaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALL
Background: Blinatumomab, inotuzumab or autologous anti-CD19 chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, tumor escape through antigenic modulation accounts for almost 40% of subsequent relapses. Multi-antigen targeting strategies should be developed, and it is urgent to identify new targets. Methods: We investigated the extensive immunophenotyping of 13 BCP-ALL from pediatric patients by using the BioLegend Human Cell Surface Marker Screening Kit. Then, to assess whether targeting each antigen with monoclonal antibodies could lead to leukemic cell lysis, long-term antibody-dependent cellular cytotoxicity (ADCC) assays were performed using murine monoclonal antibodies and human T cells armed with murine CD16. Results: 13 highly expressed antigens were selected. With the antibodies tested here, the most significant lysis was observed by targeting CD24 and CD156c. The double targeting of CD24-CD123 appeared to be even more effective. Triple targeting was associated with a reduction in ADCC activity. Conclusion: CD24 therefore emerged as an effective target in BCP-ALL, and the combination of CD24 and CD123 as a potential effective double-targeting strategy. The combination of different recognition modalities (eg, a CAR and CD16) should be tested to determine whether it provides synergistic cytotoxic activity in triple targeting.
- 2 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32134
Characterization of a Novel SREBF1::CIC Transcript in a Neonatal Soft Tissue Sarcoma
- 2 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32134
Characterization of a Novel SREBF1::CIC Transcript in a Neonatal Soft Tissue Sarcoma
- 5 September 2025
- Published by Elsevier in Bulletin du Cancer
- Vol. 112 (11) , 1342-1352
Prise en charge des saignements utérins abondants chez les patientes traitées pour une leucémie aiguë : recommandations du comité leucémie de la SFCE
- 5 September 2025
- Published by Elsevier in Bulletin du Cancer
- Vol. 112 (11) , 1342-1352
Prise en charge des saignements utérins abondants chez les patientes traitées pour une leucémie aiguë : recommandations du comité leucémie de la SFCE
- 6 March 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (10) , 1061-1073
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAF V600E loads
Hematological involvement (HI) is one of the life-threatening risk organs (ROs) in Langerhans cell histiocytosis (LCH). Lahey criteria have defined HI since 1975 as hemoglobin 20 × 109/L, respectively) and severe HI (SHI; ≤7 g/dL and/or ≤20 × 109/L). Each entity has different organ involvements, laboratory parameters, mutational status, blood BRAFV600E loads, drug sensitivities, and outcomes (MHI and SHI 10-year survival rates, 98% and 73%, respectively). Since 1998, mortality first declined with combination cladribine-cytarabine therapy and then with MAPK inhibitors since 2014. Forty-one patients (12%) developed neurodegenerative complications that have emerged as a risk for long-term survivors. These results suggest limiting the HI-RO definition to SHI, because it encompasses almost all medical complications of LCH. Future clinical trials might demonstrate that targeted therapy approaches would be better adapted for these patients, whereas MHI can be managed with classic therapies.
- 6 March 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (10) , 1061-1073
Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAF V600E loads
Hematological involvement (HI) is one of the life-threatening risk organs (ROs) in Langerhans cell histiocytosis (LCH). Lahey criteria have defined HI since 1975 as hemoglobin 20 × 109/L, respectively) and severe HI (SHI; ≤7 g/dL and/or ≤20 × 109/L). Each entity has different organ involvements, laboratory parameters, mutational status, blood BRAFV600E loads, drug sensitivities, and outcomes (MHI and SHI 10-year survival rates, 98% and 73%, respectively). Since 1998, mortality first declined with combination cladribine-cytarabine therapy and then with MAPK inhibitors since 2014. Forty-one patients (12%) developed neurodegenerative complications that have emerged as a risk for long-term survivors. These results suggest limiting the HI-RO definition to SHI, because it encompasses almost all medical complications of LCH. Future clinical trials might demonstrate that targeted therapy approaches would be better adapted for these patients, whereas MHI can be managed with classic therapies.
- Open Access
- 17 February 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (3) , 157-162
External validation of pittsburgh infant brain injury score in a French pediatric study
- 17 February 2025
- Published by Elsevier in Archives de Pédiatrie
- Vol. 32 (3) , 157-162
Open AccessExternal validation of pittsburgh infant brain injury score in a French pediatric study
- 24 September 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2406-2410
Assessing acute toxicity profiles of HLA‐identical hematopoietic stem cell transplantation in pediatric patients with sickle cell anemia: A comprehensive analysis on behalf of the SFGM‐TC
- 24 September 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (12) , 2406-2410
Assessing acute toxicity profiles of HLA‐identical hematopoietic stem cell transplantation in pediatric patients with sickle cell anemia: A comprehensive analysis on behalf of the SFGM‐TC
- Open Access
- 21 October 2023
- Published by Wiley
Impact of socioeconomic deprivation on time to diagnosis of childhood cancer
Background: In adults, there is a link between socioeconomic status (SES) and cancer prognosis, notably due to increased time to diagnosis (TTD) in deprived population leading to the spread of the disease. In children, such an association has not been clearly reported. The objective of our study was to assess the impact of SES on TTD of childhood cancer and its potential consequences on cancer prognosis. Methods: We carried out a multicenter retrospective study based on the LOGAFTER multicentric database. We studied the SES at the individual and ecological levels. Results: Overall, 854 children were included. The median time to diagnosis was 28 days [12;64]. A usual care pathway did not seem to impact TTD, but the use of alternative medicine and an initial management by professionals not usually involved in the specific childhood cancer context increased TTD. None of the SES ecological variables were strictly associated with a significant impact on TTD. However, we noted strong trends for single-parent families and children whose fathers had died who presented with an increased TTD. Conclusions: In the current study, the impact of SES on TTD in children on both the individual and ecological levels was not clear. However, we noted some keys at the individual scale that require further investigation to explain a potential association between deprivation and TTD.
- 21 October 2023
- Published by Wiley
Open AccessImpact of socioeconomic deprivation on time to diagnosis of childhood cancer
Background: In adults, there is a link between socioeconomic status (SES) and cancer prognosis, notably due to increased time to diagnosis (TTD) in deprived population leading to the spread of the disease. In children, such an association has not been clearly reported. The objective of our study was to assess the impact of SES on TTD of childhood cancer and its potential consequences on cancer prognosis. Methods: We carried out a multicenter retrospective study based on the LOGAFTER multicentric database. We studied the SES at the individual and ecological levels. Results: Overall, 854 children were included. The median time to diagnosis was 28 days [12;64]. A usual care pathway did not seem to impact TTD, but the use of alternative medicine and an initial management by professionals not usually involved in the specific childhood cancer context increased TTD. None of the SES ecological variables were strictly associated with a significant impact on TTD. However, we noted strong trends for single-parent families and children whose fathers had died who presented with an increased TTD. Conclusions: In the current study, the impact of SES on TTD in children on both the individual and ecological levels was not clear. However, we noted some keys at the individual scale that require further investigation to explain a potential association between deprivation and TTD.